{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:23:30Z","timestamp":1759483410655},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T00:00:00Z","timestamp":1205712000000},"content-version":"vor","delay-in-days":9694,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1981,9]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Seventeen undialysed adult patients with chronic renal failure took part in a controlled study of the effects of 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> and D<jats:sub>3<\/jats:sub>. After a 6\u2010month observation period the patients were allocated at random to two groups for 6 months of treatment with either 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> (mean dose 0\u00b75 \u03bcg daily) or D<jats:sub>3<\/jats:sub> (dose 100 \u03bcg daily). Treatment was then discontinued and the patients were studied for a further 6 months.<\/jats:p><jats:p>Serum iPTH was decreased in both groups but most markedly in the 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> group in which the iPTH values became normal. Serum creatinine increased during treatment in both groups. In the group receiving 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> this was coupled to an increase in serum calcium within the normal range.<\/jats:p><jats:p>Our data demonstrate that 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> treatment in patients with chronic renal failure leads to a further reduction in renal function, which may be partially reversible. Physicians should therefore be reluctant to give vitamin D analogues to patients with chronic renal failure unless they have severe symptomatic renal osteodystrophy.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1981.tb00659.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T13:06:03Z","timestamp":1205759163000},"page":"229-236","source":"Crossref","is-referenced-by-count":39,"title":["IS 1,25\u2010DIHYDROXY\u2010CHOLECALCIFEROL HARMFUL TO RENAL FUNCTION IN PATIENTS WITH CHRONIC RENAL FAILURE?"],"prefix":"10.1111","volume":"15","author":[{"given":"C.","family":"CHRISTIANSEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"R\u00d8DBRO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MERETE S.","family":"CHRISTENSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BIRGITTE","family":"HARTNACK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91137-6"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197211022871801"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92702-2"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)90498-7"},{"key":"e_1_2_1_6_1","first-page":"18","article-title":"Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1,25(OH)2D3 and 24,25(OH)2D3","volume":"15","author":"Christiansen C.","year":"1981","journal-title":"Clinical Nephrology"},{"key":"e_1_2_1_7_1","first-page":"7","article-title":"Recent advances in our understanding of the vitamin D endocrine system","volume":"87","author":"Luca H.F.","year":"1976","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"e_1_2_1_8_1","first-page":"1","article-title":"Vitamin D metabolism","volume":"7","author":"Luca H.F.","year":"1977","journal-title":"Clinical Endocrinology"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91656-2"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000403275"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91719-1"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000181749"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000403277"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.242.17.1875"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92197-1"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92220-0"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1981.tb00659.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1981.tb00659.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T13:27:42Z","timestamp":1699709262000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1981.tb00659.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1981,9]]}},"alternative-id":["10.1111\/j.1365-2265.1981.tb00659.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1981.tb00659.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,9]]}}}